RIVM recommends limiting number of e-cigarettes flavourings to 23 with tobacco taste only The government wishes to make e-cigarettes less attractive, in particular for young people.
4 in 5 COVID-19 patients in ICU are not vaccinated 4 in 5 COVID-19 patients in intensive care are not vaccinated against the coronavirus SARS-CoV-2.
Expected autumn increase in SARS-CoV-2 appears to have started In the past week from 5-12 October 2021, the reported number of people who tested positive for COVID-19 increased by 48% compared to the previous week. Reported figures increased in all regions and in all age groups.
More than health risks play a role in compliance with coronavirus measures The risk of COVID-19 is not the only factor that determines compliance with the coronavirus measures; other risks also play a role.
No evidence of more serious illness from COVID-19 among Q fever patients There are no indications that people who previously had Q fever had a more serious course of illness from the coronavirus SARS-CoV-2. This is evident from RIVM research.
Specific group of patients with impaired immunity invited in October for third COVID-19 vaccination From 6 October on, a specific group of people with severely impaired immunity (immunocompromised patients) will receive their invitation for a third vaccination against COVID-19.
State Secretary Blokhuis: boys will also be vaccinated against HPV virus The vaccine against the HPV human papillomavirus virus will also become available for boys.
A guide for the safe reuse of diaper and incontinence materials RIVM has developed a step-by-step plan for the safe reuse of diapers and incontinence material. This plan provides recyclers and licensing authorities with tools to carry out a risk assessment.
New data on greenhouse gas and ammonia emissions Greenhouse gas emissions have fallen slightly; ammonia emissions remain stable.
Humans themselves are the most important source of ESBL Antibiotic Resistance Human to human transfer is the main source of ESBL (Extended Spectrum Beta-Lactamase) antibiotic resistance, according to researchers from the ESBLAT research consortium, of which RIVM is a member.